Literature DB >> 29188282

Laboratory Monitoring During Systemic Terbinafine Therapy for Pediatric Onychomycosis.

Deepa Patel1, Leslie A Castelo-Soccio2,3, Adam I Rubin2,3,4, Jenna L Streicher2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29188282      PMCID： PMC5817446          DOI： 10.1001/jamadermatol.2017.4483

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  3 in total

1.  Onychomycosis does not always require systemic treatment for cure: a trial using topical therapy.

Authors:  Shiela Fallon Friedlander; Yuin C Chan; Yiong H Chan; Lawrence F Eichenfield
Journal:  Pediatr Dermatol       Date:  2012-12-28       Impact factor: 1.588

Review 2.  Systemic antifungals to treat onychomycosis in children: a systematic review.

Authors:  Aditya K Gupta; Maryse Paquet
Journal:  Pediatr Dermatol       Date:  2012-12-26       Impact factor: 1.588

3.  Dermatophyte onychomycosis in children.

Authors:  C M Philpot; D Shuttleworth
Journal:  Clin Exp Dermatol       Date:  1989-05       Impact factor: 3.470
  3 in total
  3 in total

1.  Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections.

Authors:  Deirdre A Stolmeier; Hannah B Stratman; Thomas J McIntee; Erik J Stratman
Journal:  JAMA Dermatol       Date:  2018-12-01       Impact factor: 10.282

Review 2.  Updated Perspectives on the Diagnosis and Management of Onychomycosis.

Authors:  Julianne M Falotico; Shari R Lipner
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-15

Review 3.  Recommendations for diagnosis and treatment of onychomycosis during the COVID-19 pandemic.

Authors:  Shari R Lipner; Jose W Ricardo
Journal:  Dermatol Ther       Date:  2020-06-25       Impact factor: 3.858
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.